Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial

Summary Background Brain scans are essential to exclude haemorrhage in patients with suspected acute ischaemic stroke before treatment with alteplase. However, patients with early ischaemic signs could be at increased risk of haemorrhage after alteplase treatment, and little information is available about whether pre-existing structural signs, which are common in older patients, affect response to alteplase. We aimed to investigate the association between imaging signs on brain CT and outcomes after alteplase. Methods IST-3 was a multicentre, randomised controlled trial of intravenous alteplase (0·9 mg/kg) versus control within 6 h of acute ischaemic stroke. The primary outcome was independence at 6 months (defined as an Oxford Handicap Scale [OHS] score of 0–2). 3035 patients were enrolled to IST-3 and underwent prerandomisation brain CT. Experts who were unaware of the random allocation assessed scans for early signs of ischaemia (tissue hypoattenuation, infarct extent, swelling, and hyperattenuated artery) and pre-existing signs (old infarct, leukoaraiosis, and atrophy). In this prespecified analysis, we assessed interactions between these imaging signs, symptomatic intracranial haemorrhage (a secondary outcome in IST-3) and independence at 6 months, and alteplase, adjusting for age, National Institutes of Health Stroke Scale (NIHSS) score, and time to randomisation. This trial is registered at ISRCTN.com, number ISRCTN25765518. Findings 3017 patients were assessed in this analysis, of whom 1507 were allocated alteplase and 1510 were assigned control. A reduction in independence was predicted by tissue hypoattenuation (odds ratio 0·66, 95% CI 0·55–0·81), large lesion (0·51, 0·38–0·68), swelling (0·59, 0·46–0·75), hyperattenuated artery (0·59, 0·47–0·75), atrophy (0·74, 0·59–0·94), and leukoaraiosis (0·72, 0·59–0·87). Symptomatic intracranial haemorrhage was predicted by old infarct (odds ratio 1·72, 95% CI 1·18–2·51), tissue hypoattenuation (1·54, 1·04–2·27), and hyperattenuated artery (1·54, 1·03–2·29). Some combinations of signs increased the absolute risk of symptomatic intracranial haemorrhage (eg, both old infarct and hyperattenuated artery, excess with alteplase 13·8%, 95% CI 6·9–20·7; both signs absent, excess 3·2%, 1·4–5·1). However, no imaging findings—individually or combined—modified the effect of alteplase on independence or symptomatic intracranial haemorrhage. Interpretation Some early ischaemic and pre-existing signs were associated with reduced independence at 6 months and increased symptomatic intracranial haemorrhage. Although no interaction was noted between brain imaging signs and effects of alteplase on these outcomes, some combinations of signs increased some absolute risks. Pre-existing signs should be considered, in addition to early ischaemic signs, during the assessment of patients with acute ischaemic stroke. Funding UK Medical Research Council, Health Foundation UK, Stroke Association UK, Chest Heart Stroke Scotland, Scottish Funding Council SINAPSE Collaboration, and multiple governmental and philanthropic national funders.

[1]  P. Sandercock Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial , 2013, The Lancet Neurology.

[2]  G. B. Young,et al.  Improved Outcomes in Stroke Thrombolysis with Pre-specified Imaging Criteria , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[3]  M. Hommel,et al.  Streptokinase in acute ischemic stroke: an individual patient data meta-analysis : The Thrombolysis in Acute Stroke Pooling Project. , 2000, Stroke.

[4]  P. Sandercock,et al.  A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[5]  D. Fatovich,et al.  Thrombolysis in acute ischaemic stroke , 2012, The Lancet.

[6]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.

[7]  Arnold B Mitnitski,et al.  The mortality rate as a function of accumulated deficits in a frailty index , 2002, Mechanisms of Ageing and Development.

[8]  P. Sandercock,et al.  Statistical Analysis Plan for the Third International Stroke Trial (IST-3); Part of a ‘Thread’ of Reports of the Trial , 2012, International journal of stroke : official journal of the International Stroke Society.

[9]  M. Allington,et al.  Thrombolysis. , 1972, Journal of clinical pathology.

[10]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .

[11]  Martin Pitt,et al.  Will Delays in Treatment Jeopardize the Population Benefit From Extending the Time Window for Stroke Thrombolysis? , 2012, Stroke.

[12]  Erich Bluhmki,et al.  Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II) , 2001, Stroke.

[13]  P. Sandercock,et al.  Third International Stroke Trial , 2006, International journal of stroke : official journal of the International Stroke Society.

[14]  J. Grotta,et al.  Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. , 2001, JAMA.

[15]  Joanna M. Wardlaw,et al.  A Large Web-Based Observer Reliability Study of Early Ischaemic Signs on Computed Tomography. The Acute Cerebral CT Evaluation of Stroke Study (ACCESS) , 2010, PloS one.

[16]  J. Slattery,et al.  Can Simple Questions Assess Outcome after Stroke , 1994 .

[17]  J. Wardlaw,et al.  A simple practical classification of cerebral infarcts on CT and its interobserver reliability. , 1994, AJNR. American journal of neuroradiology.

[18]  L Bozzao,et al.  Acute stroke: usefulness of early CT findings before thrombolytic therapy. , 1997, Radiology.

[19]  C. Jaigobin,et al.  The complexities of acute stroke decision-making , 2013, Neurology.

[20]  I. McDowell,et al.  A global clinical measure of fitness and frailty in elderly people , 2005, Canadian Medical Association Journal.

[21]  A. Demchuk,et al.  Alberta Stroke Program Early Computed Tomography Score to Select Patients for Endovascular Treatment: Interventional Management of Stroke (IMS)-III Trial , 2014, Stroke.

[22]  A. Demchuk,et al.  Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy , 2000, The Lancet.

[23]  M.W.G. Nijhuis-van der Sanden,et al.  Outcome instruments to measure frailty: A systematic review , 2011, Ageing Research Reviews.

[24]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[25]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[26]  R. Gross Spotlight on the July 2 Issue , 2013, Neurology.

[27]  S. Ellis,et al.  Tissue-plasminogen activator for acute ischaemic stroke , 1997, The Lancet.

[28]  Askiel Bruno,et al.  Tissue-plasminogen activator for acute ischaemic stroke , 1997, The Lancet.

[29]  P. Koudstaal,et al.  Grading white matter lesions on CT and MRI: a simple scale. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[30]  J. Wardlaw,et al.  Factors Influencing the Detection of Early CT Signs of Cerebral Ischemia: An Internet-Based, International Multiobserver Study , 2007, Stroke.

[31]  R. Rosenfeld Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[32]  A. Buchan,et al.  Selection of Acute Ischemic Stroke Patients for Intra-Arterial Thrombolysis With Pro-Urokinase by Using ASPECTS , 2003, Stroke.

[33]  H. Schouten,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[34]  The benefi ts and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke ( the third international stroke trial [ IST-3 ] ) : a randomised controlled trial , 2012 .

[35]  Peter Sandercock,et al.  Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis of 55 Studies , 2012, Stroke.

[36]  P. Scheltens,et al.  A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.

[37]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[38]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[39]  J. Wardlaw,et al.  Hyperdense Middle Cerebral Artery Sign on Admission CT Scan – Prognostic Significance for Ischaemic Stroke Patients Treated with Intravenous Thrombolysis in the Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Register , 2008, Cerebrovascular Diseases.

[40]  A. Demchuk,et al.  Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. , 2000, Lancet.

[41]  Brian Silver,et al.  Importance of Early Ischemic Computed Tomography Changes Using ASPECTS in NINDS rtPA Stroke Study , 2005, Stroke.

[42]  Michael D Hill,et al.  Extent of Early Ischemic Changes on Computed Tomography (CT) Before Thrombolysis: Prognostic Value of the Alberta Stroke Program Early CT Score in ECASS II , 2006, Stroke.

[43]  L Bozzao,et al.  Early prediction of irreversible brain damage after ischemic stroke at CT. , 2001, Radiology.

[44]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[45]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[46]  A. Alavi,et al.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. , 1987, AJR. American journal of roentgenology.

[47]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[48]  J. Wardlaw,et al.  Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment--systematic review. , 2005, Radiology.

[49]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.